Teachers Advisors LLC Raises Position in WAVE Life Sciences Ltd. (WVE)
Teachers Advisors LLC increased its position in shares of WAVE Life Sciences Ltd. (NASDAQ:WVE) by 64.5% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 21,534 shares of the company’s stock after acquiring an additional 8,446 shares during the period. Teachers Advisors LLC owned about 0.08% of WAVE Life Sciences worth $401,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently modified their holdings of WVE. Bank of New York Mellon Corp lifted its holdings in WAVE Life Sciences by 0.9% during the 1st quarter. Bank of New York Mellon Corp now owns 31,350 shares of the company’s stock worth $862,000 after buying an additional 279 shares during the period. American International Group Inc. lifted its holdings in WAVE Life Sciences by 7.1% during the 1st quarter. American International Group Inc. now owns 4,554 shares of the company’s stock worth $125,000 after buying an additional 302 shares during the period. Strs Ohio lifted its holdings in WAVE Life Sciences by 6.3% during the 2nd quarter. Strs Ohio now owns 11,900 shares of the company’s stock worth $221,000 after buying an additional 700 shares during the period. Schwab Charles Investment Management Inc. lifted its holdings in WAVE Life Sciences by 6.5% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 30,707 shares of the company’s stock worth $845,000 after buying an additional 1,881 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in WAVE Life Sciences by 4.6% during the 1st quarter. Geode Capital Management LLC now owns 76,478 shares of the company’s stock worth $2,103,000 after buying an additional 3,397 shares during the period. Institutional investors and hedge funds own 69.53% of the company’s stock.
WVE has been the topic of a number of recent analyst reports. Mizuho set a $34.00 price objective on WAVE Life Sciences and gave the company a “buy” rating in a research note on Friday, August 18th. BidaskClub raised WAVE Life Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, August 26th. Jefferies Group LLC reissued a “buy” rating and issued a $40.00 price objective (down from $42.00) on shares of WAVE Life Sciences in a research note on Thursday, August 10th. Finally, Zacks Investment Research raised WAVE Life Sciences from a “sell” rating to a “hold” rating in a research note on Thursday, October 12th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $38.75.
WAVE Life Sciences Ltd. (NASDAQ:WVE) opened at $24.75 on Wednesday. The company has a current ratio of 11.50, a quick ratio of 11.50 and a debt-to-equity ratio of 0.01. WAVE Life Sciences Ltd. has a 52 week low of $15.15 and a 52 week high of $40.15.
WAVE Life Sciences (NASDAQ:WVE) last announced its quarterly earnings data on Thursday, November 9th. The company reported ($0.94) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.03. The company had revenue of $0.68 million for the quarter, compared to the consensus estimate of $0.77 million. WAVE Life Sciences had a negative return on equity of 59.52% and a negative net margin of 3,338.68%. research analysts anticipate that WAVE Life Sciences Ltd. will post -3.75 EPS for the current year.
In related news, Director Masaharu Tanaka sold 20,747 shares of the business’s stock in a transaction dated Monday, September 18th. The stock was sold at an average price of $24.21, for a total value of $502,284.87. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 53.00% of the stock is owned by insiders.
WAVE Life Sciences Profile
WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
Receive News & Ratings for WAVE Life Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.